Despite showing promising results in rodent models, the galectin-3 inhibitor belapectin (GR-MD-02) did not alleviate fibrosis in a phase 2 trial in patients with NASH with cirrhosis and portal hypertension (187, 188). This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.